4-fluoro-1,4'-bipiperidine | 864291-95-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-fluoro-1,4'-bipiperidine
• 英文别名: 4-fluoro-1-piperidin-4-ylpiperidine
• CAS: 864291-95-2
• 化学式: C₁₀H₁₉FN₂
• 分子量: 186.273
• InChiKey: HCOPLSQKRZCIPU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-fluoro-1,4'-bipiperidine 、 2-chloro-N-cycloheptyl-6,7-dimethoxyquinazolin-4-amine 在 N,N-二异丙基乙胺 作用下， 以 正丁醇 为溶剂， 以94%的产率得到N-cycloheptyl-2-(4-(4-fluoropiperidin-1-yl)piperidin-1-yl)-6,7-dimethoxyquinazolin-4-amine
  参考文献：
  名称：

  Discovery of potent CCR4 antagonists: Synthesis and structure–activity relationship study of 2,4-diaminoquinazolines

  摘要：

  A new series of quinazolines that function as CCR4 antagonists were discovered during the screening of our corporate compound libraries. Subsequent compound optimization elucidated the structure-activity relationships and led the identification of 2-(1,4'-bipiperidine-10-yl)-N-cycloheptyl-6,7-dimethoxyquinazolin-4- amine 14a, which showed potent inhibition in the [S-35] GTPcS-binding assay (IC50 = 18 nM). This compound also inhibited the chemotaxis of human and mouse CCR4-expressing cells ( IC50 = 140 nM, 39 nM). (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.05.036
• 作为产物：
  描述：

  4-羟基哌啶 在 盐酸 、 溶剂黄146 、 [双(2-甲氧基乙基)胺]三氟化硫 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 41.5h， 生成 4-fluoro-1,4'-bipiperidine
  参考文献：
  名称：

  [EN] TRPV4 ANTAGONISTS
  [FR] ANTAGONISTES DE TRPV4

  摘要：

  本发明涉及喹啉类似物、含有它们的药物组合物以及它们作为TRPV4拮抗剂的用途。

  公开号：

  WO2011119701A1

文献信息

• FUSED PYRIMIDINE COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND APPLICATION THEREOF
  申请人：SHANGHAI YINGLI PHARMACEUTICAL CO., LTD

  公开号：US20160214994A1

  公开（公告）日：2016-07-28

  Disclosed are a fused pyrimidine compound, an intermediate, a preparation method therefor, and a composition and an application thereof. The present invention provides a fused pyrimidine compound shown in formula I, pharmaceutically acceptable salt, hydrate, solvate, and an optical isomer or prodrug of the compound. The present invention further provides applications of the fused pyrimidine compound shown in formula I, the pharmaceutically acceptable salt, the hydrate, solvate, and the optical isomer or the prodrug of the compound in the preparing drugs for curing and/or preventing a kinase-related disease. The fused pyrimidine compound I of the present invention is an efficient PI3 kinase depressor, and can be used to prepare drugs for preventing and/or curing cell-proliferation diseases such as cancer, infection, inflammation, and an autoimmune disease.

  揭示了一种融合嘧啶化合物，其中间体，制备方法以及其组成和应用。本发明提供了一种如式I所示的融合嘧啶化合物，该化合物的药用可接受盐，水合物，溶剂合物，以及光学异构体或前药。本发明还提供了应用式I所示的融合嘧啶化合物，药用可接受盐，水合物，溶剂合物，以及该化合物的光学异构体或前药在制备用于治疗和/或预防激酶相关疾病的药物中。本发明的融合嘧啶化合物I是一种高效的PI3激酶抑制剂，可用于制备用于预防和/或治疗细胞增殖性疾病，如癌症，感染，炎症和自身免疫疾病的药物。
• [EN] 1, 7 - DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER<br/>[FR] 1,7-DIAZACARBAZOLES ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011073263A1

  公开（公告）日：2011-06-23

  The invention relates to 1, 7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk 1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

  这项发明涉及式(I)、(I-a)和(I-b)的1,7-二氮杂咔唑化合物，这些化合物可用作激酶抑制剂，更具体地用作检查点激酶1（chk 1）抑制剂，因此可用作癌症治疗剂。该发明还涉及含有这些化合物的组合物，更具体地是含有这些化合物的药物组合物，以及使用它们来治疗各种癌症和过度增殖性疾病的方法，以及使用这些化合物进行哺乳动物细胞的体外、体内和体外诊断或治疗以及相关病理情况的方法。
• 1-Oxo-3,4-dihydroisoquinoline-4-carboxamides as novel druglike inhibitors of poly(ADP-ribose) polymerase (PARP) with favourable ADME characteristics
  作者：Alexander Safrygin、Petr Zhmurov、Dmitry Dar’in、Sergey Silonov、Mariia Kasatkina、Yulia Zonis、Maxim Gureev、Mikhail Krasavin

  DOI：10.1080/14756366.2021.1972993

  日期：2021.1.1

  scaffold was designed as the basis for the development of novel inhibitors of poly(ADP-ribose) polymerase (PARP). Synthesis of 3,4-dihydroisoquinol-1-one-4-carboxylic acids was achieved using the previously developed protocol based on the modified Castagnoli-Cushman reaction of homophthalic anhydrides and 1,3,5-triazinanes as formaldimine synthetic equivalents. Employment of 2,4-dimethoxy groups on the nitrogen

  摘要 一种新型 3,4-二氢异羟基喹啉-1-one-4-carboxamide 支架被设计为开发新型聚 (ADP-核糖) 聚合酶 (PARP) 抑制剂的基础。3,4-二氢异喹啉-1-one-4-羧酸的合成是使用先前开发的协议实现的，该协议基于同邻苯二甲酸酐和 1,3,5-三嗪烷作为甲醛亚胺合成等价物的改良 Castagnoli-Cushman 反应。在后者的氮原子上使用 2,4-二甲氧基允许制备 2,3-未取代的 3,4-二氢喹诺酮核心构件。由这些羧酸的酰胺化产生的酰胺的迭代合成和体外生物测试不仅允许绘制重要的结构-活性概括（由in silico证实）对接模拟）以及先导化合物 4-([1,4'-bipiperidine]-1'-carbonyl)-7-fluoro-3,4-dihydroisoquinolin-1(2 H )-one的鉴定，作为进一步临床前开发的候选者。先导化合物及其脱氟类似物与获批的
• 1,7-DIAZACARBAZOLES AND METHODS OF USE
  申请人：Dyke Hazel Joan

  公开号：US20110183938A1

  公开（公告）日：2011-07-28

  The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

  该发明涉及1,7-二氮杂咔唑化合物的公式（I）、（I-a）和（I-b），它们可用作激酶抑制剂，更具体地用作检查点激酶1（CHK1）抑制剂，因此可用作癌症治疗剂。该发明还涉及包含这些化合物的组合物，更具体地是药物组合物，以及使用它们治疗各种癌症和高增殖性疾病的方法，以及使用这些化合物进行哺乳动物细胞的体外、原位和体内诊断或治疗，或相关病理条件的方法。
• TRPV4 antagonists
  申请人：Brooks Carl A.

  公开号：US08658636B2

  公开（公告）日：2014-02-25

  The present invention relates to quinoline analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.

  本发明涉及喹啉类似物、含有它们的药物组成物以及它们作为TRPV4拮抗剂的用途。